The stock of Alpine Immune Sciences Inc (ALPN) has seen a 0.03% increase in the past week, with a 64.73% gain in the past month, and a 142.73% flourish in the past quarter. The volatility ratio for the week is 0.18%, and the volatility levels for the past 30 days are at 3.97% for ALPN. The simple moving average for the last 20 days is 13.70% for ALPN stock, with a simple moving average of 182.60% for the last 200 days.
Is It Worth Investing in Alpine Immune Sciences Inc (NASDAQ: ALPN) Right Now?
The 36-month beta value for ALPN is also noteworthy at 0.97. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALPN is 47.36M, and at present, short sellers hold a 10.01% of that float. The average trading volume of ALPN on May 01, 2024 was 2.19M shares.
ALPN) stock’s latest price update
The stock price of Alpine Immune Sciences Inc (NASDAQ: ALPN) has plunged by 0.00 when compared to previous closing price of 64.59, but the company has seen a 0.03% gain in its stock price over the last five trading sessions. InvestorPlace reported 2024-04-15 that Wise investors are placing some biotech stocks on their watchlists this month, as these companies have surged over 160%. With more predicted upside to these companies than we see today, one could book some serious capital appreciation into a portfolio.
Analysts’ Opinion of ALPN
Many brokerage firms have already submitted their reports for ALPN stocks, with Guggenheim repeating the rating for ALPN by listing it as a “Buy.” The predicted price for ALPN in the upcoming period, according to Guggenheim is $55 based on the research report published on April 09, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see ALPN reach a price target of $44. The rating they have provided for ALPN stocks is “Outperform” according to the report published on February 15th, 2024.
Berenberg gave a rating of “Buy” to ALPN, setting the target price at $18 in the report published on October 18th of the previous year.
ALPN Trading at 44.40% from the 50-Day Moving Average
After a stumble in the market that brought ALPN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.20% of loss for the given period.
Volatility was left at 3.97%, however, over the last 30 days, the volatility rate increased by 0.18%, as shares surge +69.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +111.73% upper at present.
During the last 5 trading sessions, ALPN rose by +0.05%, which changed the moving average for the period of 200-days by +468.66% in comparison to the 20-day moving average, which settled at $58.13. In addition, Alpine Immune Sciences Inc saw 238.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALPN starting from Topper James N, who sale 19 shares at the price of $64.57 back on Apr 25 ’24. After this action, Topper James N now owns 2,829,347 shares of Alpine Immune Sciences Inc, valued at $1,227 using the latest closing price.
Rickey James Paul, the See Remarks of Alpine Immune Sciences Inc, sale 117,764 shares at $23.32 during a trade that took place back on Jan 26 ’24, which means that Rickey James Paul is holding 0 shares at $2,745,830 based on the most recent closing price.
Stock Fundamentals for ALPN
Current profitability levels for the company are sitting at:
- -0.75 for the present operating margin
- 0.99 for the gross margin
The net margin for Alpine Immune Sciences Inc stands at -0.51. The total capital return value is set at -0.13. Equity return is now at value -12.69, with -9.63 for asset returns.
Based on Alpine Immune Sciences Inc (ALPN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.97. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 451.53.
Currently, EBITDA for the company is -43.67 million with net debt to EBITDA at 0.94. When we switch over and look at the enterprise to sales, we see a ratio of 71.35. The receivables turnover for the company is 78.61for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.86.
Conclusion
In summary, Alpine Immune Sciences Inc (ALPN) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
